1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

Western European Companion Diagnostics Market

  • May 2014
  • 164 pages
  • Frost & Sullivan
Report ID: 2148683

Summary

Table of Contents

Regulatory Hurdles and LDTs Stall the Global and European Market for Companion Diagnostics

The research service aims to give a global outlook of the companion diagnostic market landscape, with a specific focus on Western European countries. The segments related to oncology discussed in this study include breast cancer, lung cancer, colorectal cancer and other cancers, and non-oncology related infectious disease, CNS, and cardiovascular. The forecasts are based on test volumes for these cancers and disease types. Effective analysis of the reimbursement pathway in Germany, the United Kingdom, France, Italy, Spain, Scandinavia, and Benelux, coupled with regulatory approval in Europe, is discussed. A comparative assessment of regulatory scenarios has been performed to assess easy-target markets.

Key Findings

-The molecular diagnostics sector and tissue diagnostics sector form the basis of the companion diagnostics market. Most partnerships are triggered by growth and innovation in these sectors. The companion diagnostics market is valued at $ million and is expected to reach $ billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of % from 2013 to 2018.
-Approximately % of the market is focused on oncology-based testing products, while % of the market is focused on non-oncology areas. By 2016 and 2017, Frost and Sullivan expects that the non-oncology sector will gradually experience an increase because many companies such as QIAGEN and Roche have a strong pipeline for infectious diseases and central nervous system (CNS) areas. Many pharmaceutical giants are focusing on developing new treatments for neurodegenerative disorders.
- Within oncology testing, breast cancer, lung cancer, and colorectal cancer represent the major portion of the testing market as more CE IVD companion diagnostic products exist in the European market.
-From 2014 onward, Europe will portray an interesting geography because of the effect of the new revised IVD regulation and clinical trial regulation. Frost & Sullivan anticipates this modification to have both positive and negative effects on companion diagnostics manufacturers.
- The new rule is aligned with the International Medical Device Regulators Forum (IMDRF), formerly known as Global Harmonization Task Force (GHTF), and is expected to address challenges pertaining to laboratory-developed tests (LDT).
- Among the various companion diagnostic products, breast cancer testing has matured, exhibiting an established market space indicated by a moderate growth rate.
- Given the recent approvals for many combination products, lung cancer testing is the most attractive growth market. About % of partnerships worldwide are focused on lung cancer as the therapeutic area, followed by colorectal cancer testing.
- Amidst other types, tests for cancer, melanoma, prostate, and ovarian cancers will experience growth in the upcoming years.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • Industry report
  • June 2017
  • by Datamonitor Healthcare

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. Incidence rates are highest in sub-Saharan Africa, Latin ...

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

CAR-T Disease Outlook [2017]

  • $ 8355
  • Industry report
  • June 2017
  • by Firstword Pharma

Will CAR-T cell therapies shape the treatment of blood cancers in the next decade? Anti-CD19 CAR-T cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.